Who are FLU-Q-PAN H7N9 Formulation 2's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Intranasal Influenza Live Attenuated Vaccine, H5N1 vaccine (Arepanrix), FluMist trivalent (2015-2016), inactivated split-virus influenza vaccine, Fluarix Tetra Vaccine, Trivalent sub-unit influenza vaccine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/flu-q-pan-h7n9-formulation-2.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

FLU-Q-PAN H7N9 Formulation 2 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

FLU-Q-PAN H7N9 Formulation 2 (FLU-Q-PAN H7N9 Formulation 2) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Influenza vaccine. Area: Infectious disease.

phase 2 Influenza vaccine Infectious disease Biologic Live · refreshed every 30 min

Target snapshot

FLU-Q-PAN H7N9 Formulation 2 (FLU-Q-PAN H7N9 Formulation 2) — GlaxoSmithKline. FLU-Q-PAN H7N9 Formulation 2 is a vaccine designed to protect against H7N9 influenza.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
FLU-Q-PAN H7N9 Formulation 2 TARGET	FLU-Q-PAN H7N9 Formulation 2	GlaxoSmithKline	phase 2	Influenza vaccine
Intranasal Influenza Live Attenuated Vaccine	Intranasal Influenza Live Attenuated Vaccine	Jiangsu Province Centers for Disease Control and Prevention	marketed	Live attenuated influenza vaccine
H5N1 vaccine (Arepanrix)	H5N1 vaccine (Arepanrix)	Canadian Immunization Research Network	marketed	inactivated split-virion influenza vaccine with adjuvant
FluMist trivalent (2015-2016)	FluMist trivalent (2015-2016)	MedImmune LLC	marketed	Live attenuated influenza vaccine
inactivated split-virus influenza vaccine	inactivated split-virus influenza vaccine	The Cleveland Clinic	marketed	inactivated influenza vaccine
Fluarix Tetra Vaccine	Fluarix Tetra Vaccine	GlaxoSmithKline	marketed	Inactivated influenza vaccine
Trivalent sub-unit influenza vaccine	Trivalent sub-unit influenza vaccine	University of Witwatersrand, South Africa	marketed	inactivated influenza vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Influenza vaccine class)

GlaxoSmithKline · 8 drugs in this class
Sanofi Pasteur, a Sanofi Company · 2 drugs in this class
Seqirus · 2 drugs in this class
MedImmune LLC · 1 drug in this class
AstraZeneca · 1 drug in this class
Novartis · 1 drug in this class
Protein Sciences Corporation · 1 drug in this class
ModernaTX, Inc. · 1 drug in this class
Institute of Vaccines and Medical Biologicals, Vietnam · 1 drug in this class
Janssen Vaccines & Prevention B.V. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). FLU-Q-PAN H7N9 Formulation 2 — Competitive Intelligence Brief. https://druglandscape.com/ci/flu-q-pan-h7n9-formulation-2. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab